3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Gynecologic
1
Genitourinary
1
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Thromboembolism of Vein VTE in Colorectal Cancer
1
Thromboembolism
1
Pulmonary Embolism
1
Pancreatic Neoplasms
1
Interventions
Oxaliplatin
1413
Fluorouracil
1301
Capecitabine
1087
Gemcitabine
1045
Leucovorin
932
Irinotecan
818
Bevacizumab
804
Cisplatin
669
Radiotherapy
536
Cetuximab
470
pembrolizumab
428
Paclitaxel
390
Nivolumab
337
130-nm albumin-bound paclitaxel
325
Drug Therapy
314
Docetaxel
287
S 1 (combination)
274
Sorafenib
266
Folfox protocol
261
Albumin-Bound Paclitaxel
259
sintilimab
211
durvalumab
210
Surgical Procedures, Operative
204
tislelizumab
203
Radiosurgery
202
lenvatinib
201
apatinib
200
Carboplatin
187
Magnetic Resonance Spectroscopy
183
regorafenib
181
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
isoquercitrin
×
Gastrointestinal
×
Clear all
NCT06861088
2026-02-02
CATIQ P3
Quercis Pharma AG
Phase 3
Recruiting
480 enrolled
NCT02195232
2021-03-03
CATIQ
Dana-Farber Cancer Institute
Phase 2/3
Completed
64 enrolled
7 charts